City State Bank Sells 1,387 Shares of Johnson & Johnson (NYSE:JNJ)

City State Bank decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,111 shares of the company’s stock after selling 1,387 shares during the period. City State Bank’s holdings in Johnson & Johnson were worth $1,751,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of JNJ. Highline Wealth Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $40,000. Finally, Morton Brown Family Wealth LLC raised its stake in Johnson & Johnson by 400.0% during the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock worth $41,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Bank of America reaffirmed a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Finally, Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $174.71.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 0.7 %

Shares of Johnson & Johnson stock traded up $1.01 on Monday, hitting $143.07. The company had a trading volume of 1,793,724 shares, compared to its average volume of 7,099,075. The stock has a market capitalization of $344.46 billion, a price-to-earnings ratio of 20.70, a P/E/G ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a 50 day moving average of $149.67 and a 200-day moving average of $156.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.66 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.47%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.